Skip to main content

Table 4 Multivariate analysis of MYC and BCL2 coexpression and prognostic scoring systems for progression-free survival in patients with PCNS-DLBCL treated with combined MVP and radiotherapy

From: MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system

  HR 95 % CI P
Age 0.983 0.922–1.049 0.605
N-B, 2–3 1.146 0.464–2.830 0.768
MSKCC, 2–3 4.975 0.715–34.613 0.105
MYC (≥40) and BCL2 (≥60), dual positive 4.372 1.430–13.367 0.010
  1. Abbreviations: PFS progression-free survival, HR hazard ratio, CI confidence interval, N-B Nottingham- Barcelona, MSKCC Memorial Sloan Kettering Cancer Center